Arcus Biosciences Inc (RCUS) Stock Analysis

Arcus Biosciences Inc (RCUS) is a publicly traded company in the HEALTHCARE sector. It trades at $24.46, carries a market capitalization of $3.23B. This page summarizes the public market data, fundamentals, and frequently asked questions for RCUS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NYSE

Key Metrics

Market Sentiment

Arcus Biosciences Inc currently has a Neutral sentiment score of -0.02.

About Arcus Biosciences Inc

Arcus Biosciences, Inc. (RCUS) is a clinical-stage biopharmaceutical company headquartered in Hayward, California, dedicated to revolutionizing cancer treatment through its innovative pipeline of immune-oncology and targeted therapies. The company leverages proprietary platforms and strategic collaborations to develop cutting-edge therapies aimed at empowering the immune system to combat tumors. With a strong commitment to improving patient outcomes, Arcus is uniquely positioned for substanti...

GNG Research Analysis

GNG Research scores Arcus Biosciences Inc (RCUS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for RCUS.

Frequently Asked Questions

Does RCUS pay dividends?

Arcus Biosciences Inc (RCUS) does not currently pay a regular dividend.

What is RCUS's market cap?

Arcus Biosciences Inc (RCUS) has a market capitalization of $3.23B with a current stock price of $24.46.